Hensen J, Haenelt M, Gross P
Department of Medicine, Universitäts-Klinikum Steglitz, Freie Universtiät Berlin, Germany.
Nephrol Dial Transplant. 1996 Apr;11(4):622-7. doi: 10.1093/oxfordjournals.ndt.a027350.
Lithium, a drug frequently used for treatment of affective disorders, is known to cause a vasopressin-resistant state, leading to polyuria and polydipsia. It has been suggested that lithium interacts with the renal V2-vasopressin receptor. Detailed studies on the influence of lithium on the AVP receptor, however, have so far been difficult due to the lack of a suitable radioligand with high specific activity and high affinity.
Using 125I-[8-(p-(OH)-phenylpropionyl)]- LVP, we studied the effects of lithium on V2-vasopressin receptors in male Sprague-Dawley rats and LLC-PK1 cells. Rats, having free access to water, were orally treated with 10 mg lithium/100 mg b.w./day or placebo for 10 days. Scatchard analysis was performed using membranes prepared from homogenized renal papillae.
Lithium caused significant polyuria and an impaired renal concentration capacity after water deprivation. Binding studies showed no effect of lithium on binding affinity KD (0.98 +/- 0.21 nmol/l vs. 0.86 +/- 0.15 nmol/l (Li) (n.s.). Receptor density, however, significantly decreased from 130 +/- 12.3 nmol/kg protein in controls (n = 8) to 101.7 +/- 13.4 nmol/kg protein (n = 8), (P < 0.05). Plasma osmotically and AVP were not significantly altered by lithium treatment. Vasopressin receptor density on LLC-PK1-cells, a pig renal cell line, was not changed by preincubation with lithium (312 +/- 22 nmol/kg vs. 329 +/- 25 nmol/kg (Li) (n = 6, n.s.).
The decrease of AVP-receptor density in vivo might be related to vasopressin resistance, either primary, or secondary to other factors, e.g. actual water transport.
锂是一种常用于治疗情感障碍的药物,已知会导致抗血管加压素状态,从而引起多尿和烦渴。有人提出锂与肾脏V2 - 血管加压素受体相互作用。然而,由于缺乏具有高比活性和高亲和力的合适放射性配体,迄今为止对锂对血管加压素受体影响的详细研究一直很困难。
我们使用125I - [8 - (对 - (OH) - 苯丙酰基)] - LVP,研究了锂对雄性Sprague - Dawley大鼠和LLC - PK1细胞中V2 - 血管加压素受体的影响。自由饮水的大鼠每天口服10 mg锂/100 mg体重或安慰剂,持续10天。使用从匀浆肾乳头制备的膜进行Scatchard分析。
锂导致明显的多尿以及禁水后肾脏浓缩能力受损。结合研究表明锂对结合亲和力KD没有影响(0.98±0.21 nmol/l对0.86±0.15 nmol/l(锂)(无显著性差异)。然而,受体密度从对照组的130±12.3 nmol/kg蛋白质显著降低至101.7±13.4 nmol/kg蛋白质(n = 8),(P < 0.05)。锂治疗对血浆渗透压和血管加压素没有显著改变。猪肾细胞系LLC - PK1细胞上的血管加压素受体密度在与锂预孵育后没有变化(312±22 nmol/kg对329±25 nmol/kg(锂)(n = 6,无显著性差异)。
体内血管加压素受体密度的降低可能与血管加压素抵抗有关,这种抵抗可能是原发性的,或者是继发于其他因素,例如实际的水转运。